Table 5.

Treatment decisions after IUS.

	CD examinations [n = 280]	UC examinations [n = 65]
No change	106 [37.9%]	32 [49.2%]
Imaging n = 122	104	18
Endoscopy
Total	73[26.1%]	16 [24.6%]
Dilation stricture	13 [12.3%]	-
MRI	23 [8.6%]	1 [3.1%]
CT scan	8 [3.5%]	1 [3.1%]
Medication change n = 99
Biologics
Start	25 [8.9%]	3 [4.6%]
Dose intensification	4 [1.4%]	3 [4.6%]
Dose de-escalation	1 [0.4%]	-
Stop	1 [0.4%]	-
Immunomodulators
Start	23 [8.2%]	3 [4.6%]
Stop	2 [0.7%]	1 [1.5%]
Tofacitinib	-	1 [1.5%]
Stop
Corticosteroids [oral/topical]
Start	9 [3.2%]	4 [6.2%]
Stop	1 [0.5%]	-
Budesonide
Start	8 [2.9%]	1 [1.5%]
Stop	-	1 [1.5%]
5-ASA	0 [0%]	6 [9.2%]
Inclusion in clinical trial	1 [0.5%]	1 [1.5%]
Surgical resection
Total	16 [5.7%]	-

IUS, intestinal ultrasound; CD, Crohn’s disease; UC, ulcerative colitis; MRI, magnetic resonance imaging; CT, computed tomography; 5-ASA, 5-aminosalicylate